Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 receptor agonists for visceral adipose tissue in NAFLD with type 2 diabetes
ChiCTR2100043046Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin in metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes mellitus (T2DM) and Abdominal adiposity (ABCD) (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: visceral fat content. Started Jan 2021; status: recruiting.
02
Drugs
metformin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)Abdominal adiposity (ABCD)
Beyond the preview
Go deeper on ChiCTR2100043046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043046.